Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.53%87.991.3%$894.47m
AMGNAmgen Inc.
0.04%191.311.2%$560.48m
ONCESpark Therapeutics, Inc.
0.33%113.9611.2%$458.43m
GILDGilead Sciences, Inc.
-0.93%65.020.9%$450.52m
BIIBBiogen Inc.
-1.28%325.651.3%$354.96m
BPTHBio-Path Holdings, Inc.
-5.48%27.79190.1%$296.94m
REGNRegeneron Pharmaceuticals, Inc.
-1.66%407.602.6%$280.72m
ILMNIllumina, Inc.
-1.31%305.783.5%$269.47m
VRTXVertex Pharmaceuticals Incorporated
-0.32%187.481.9%$245.27m
SRPTSarepta Therapeutics, Inc.
-1.20%126.8215.4%$210.77m
EXASExact Sciences Corporation
-3.44%91.9325.3%$194.56m
ALXNAlexion Pharmaceuticals, Inc.
-1.90%133.512.0%$181.24m
AAgilent Technologies, Inc.
-0.16%80.971.6%$153.74m
IONSIonis Pharmaceuticals, Inc.
1.25%79.528.3%$101.55m
BMRNBioMarin Pharmaceutical Inc.
-1.24%93.364.3%$97.41m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.